 |
471 Diseases |  |
207 Trials |
|
207 Trials |  |
10577 News |  |
| «12...116117118119120121122123124125126...132133» |
- Signifor (pasireotide) / Recordati
Trial primary completion date: Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases (clinicaltrials.gov) - May 18, 2014
P1/2, N=49, Recruiting, Sponsor: Emory University
Trial primary completion date: Dec 2013 --> Dec 2015
- lenalidomide / Generic mfg., everolimus / Generic mfg.
Trial primary completion date, Combination therapy, Metastases: Study of Everolimus (RAD001) in Combination With Lenalidomide (clinicaltrials.gov) - May 18, 2014
P1, N=45, Recruiting, Sponsor: Emory University
Trial primary completion date: Dec 2013 --> Dec 2015 Trial primary completion date: Dec 2013 --> Dec 2014
- | buparlisib (AN2025) / Novartis, Adlai Nortye
Trial completion date, Metastases: A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies (clinicaltrials.gov) - May 18, 2014
P1, N=53, Recruiting, Sponsor: Emory University
Trial primary completion date: Dec 2013 --> Dec 2014 Trial completion date: Feb 2015 --> Feb 2016
- Signifor (pasireotide) / Recordati
Trial completion date: Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases (clinicaltrials.gov) - May 18, 2014
P1/2, N=49, Recruiting, Sponsor: Emory University
Trial completion date: Feb 2015 --> Feb 2016 Trial completion date: Dec 2014 --> Mar 2016
- New P2 trial, Metastases: MetAction: N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy (clinicaltrials.gov) - May 18, 2014
P2, N=50, Not yet recruiting, Sponsor: Oslo University Hospital
- |||| everolimus / Generic mfg., exemestane / Generic mfg.
Enrollment open, Metastases: Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - May 14, 2014
P2, N=97, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Dec 2014 --> Mar 2016 Not yet recruiting --> Recruiting
- || letrozole / Generic mfg., everolimus / Generic mfg.
Trial primary completion date, Combination therapy, Metastases: Bolero-4: Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - May 14, 2014
P2, N=200, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Trial primary completion date: Oct 2016 --> Feb 2016
- || letrozole / Generic mfg., everolimus / Generic mfg.
Trial completion date, Combination therapy, Metastases: Bolero-4: Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - May 14, 2014
P2, N=200, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Oct 2016 --> Feb 2016 Trial completion date: Oct 2016 --> Feb 2016
- || Avastin (bevacizumab) / Roche
Trial primary completion date: Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial (clinicaltrials.gov) - May 13, 2014
P2, N=240, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Oct 2016 --> Feb 2016 Trial primary completion date: Jan 2015 --> Jan 2016
- || Sutent (sunitinib) / Pfizer
Trial primary completion date, Metastases: ASPEN: Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (clinicaltrials.gov) - May 13, 2014
P2, N=108, Active, not recruiting, Sponsor: Duke University
Trial primary completion date: Jan 2015 --> Jan 2016 Trial primary completion date: Sep 2014 --> Mar 2015
- || Sutent (sunitinib) / Pfizer
Trial completion date, Metastases: ASPEN: Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (clinicaltrials.gov) - May 13, 2014
P2, N=108, Active, not recruiting, Sponsor: Duke University
Trial primary completion date: Sep 2014 --> Mar 2015 Trial completion date: Sep 2015 --> Mar 2016
- | Odomzo (sonidegib) / Sun Pharma
New P1 trial, Combination therapy, Metastases: LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma (clinicaltrials.gov) - May 13, 2014
P1, N=42, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- everolimus / Generic mfg., capecitabine / Generic mfg.
Trial primary completion date: A Trial of RAD001/Capecitabine in Refractory Gastric Cancer (clinicaltrials.gov) - May 12, 2014
P1/2, N=59, Completed, Sponsor: Samsung Medical Center
Trial completion date: Sep 2015 --> Mar 2016 Trial primary completion date: Mar 2012 --> Aug 2013
- everolimus / Generic mfg., capecitabine / Generic mfg.
Trial completion date: A Trial of RAD001/Capecitabine in Refractory Gastric Cancer (clinicaltrials.gov) - May 12, 2014
P1/2, N=59, Completed, Sponsor: Samsung Medical Center
Trial primary completion date: Mar 2012 --> Aug 2013 Trial completion date: Apr 2012 --> Dec 2013
- everolimus / Generic mfg., capecitabine / Generic mfg.
Trial completion: A Trial of RAD001/Capecitabine in Refractory Gastric Cancer (clinicaltrials.gov) - May 12, 2014
P1/2, N=59, Completed, Sponsor: Samsung Medical Center
Trial completion date: Apr 2012 --> Dec 2013 Recruiting --> Completed
- || Trial primary completion date: Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment. (clinicaltrials.gov) - May 11, 2014
P2, N=57, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
- || Trial completion date: Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment. (clinicaltrials.gov) - May 11, 2014
P2, N=57, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Trial completion date: Apr 2014 --> Aug 2014
- ||||| Herceptin (trastuzumab) / Roche
Enrollment closed, Combination therapy, Metastases: BOLERO-1: Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - May 11, 2014
P3, N=719, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Apr 2014 --> Aug 2014 Recruiting --> Active, not recruiting
- |||||||||| anastrozole / Generic mfg., everolimus / Generic mfg., fulvestrant / Generic mfg.
Metastases: S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer (clinicaltrials.gov) - May 11, 2014
P3, N=825, Not yet recruiting, Sponsor: Southwest Oncology Group
- ||||| Nulojix (belatacept) / BMS
Clinical: Regimen Optimization Study (clinicaltrials.gov) - May 11, 2014
P2, N=240, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- ||| everolimus / Generic mfg.
New P3 trial: EVERKYSTE: The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients (clinicaltrials.gov) - May 7, 2014
P3, N=40, Not yet recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
- || Mekinist (trametinib) / Novartis, BeiGene
Trial primary completion date: GSK1120212 Rollover Study (clinicaltrials.gov) - May 7, 2014
P2, N=200, Recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Trial primary completion date: Oct 2015 --> Jun 2018
- || Mekinist (trametinib) / Novartis, BeiGene
Trial completion date: GSK1120212 Rollover Study (clinicaltrials.gov) - May 7, 2014
P2, N=200, Recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Oct 2015 --> Jun 2018 Trial completion date: Oct 2015 --> Jun 2018
- ||| everolimus / Generic mfg., exemestane / Generic mfg.
Trial initiation date, Metastases: Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - May 7, 2014
P2, N=97, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Oct 2015 --> Jun 2018 Initiation date: Mar 2014 --> May 2014
- Nulojix (belatacept) / BMS
Clinical: Belatacept for Renal Transplant Recipients With Delayed Graft Function (clinicaltrials.gov) - May 7, 2014
P0, N=40, Recruiting, Sponsor: Von Visger, Jon, MD
- || everolimus / Generic mfg.
Trial primary completion date, Monotherapy, Metastases: MACS0460: RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe (clinicaltrials.gov) - May 7, 2014
P2, N=60, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Mar 2014 --> May 2014 Trial primary completion date: Feb 2014 --> Dec 2014
- || everolimus / Generic mfg.
Trial completion date, Monotherapy, Metastases: MACS0460: RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe (clinicaltrials.gov) - May 7, 2014
P2, N=60, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Feb 2014 --> Dec 2014 Trial completion date: Feb 2014 --> Dec 2014
- Enrollment open: Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors (clinicaltrials.gov) - May 6, 2014
P=N/A, N=12, Recruiting, Sponsor: Seattle Children's Hospital
Trial completion date: Feb 2014 --> Dec 2014 Active, not recruiting --> Recruiting
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Clinical: RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia (clinicaltrials.gov) - May 5, 2014
P1/2, N=42, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Recruiting Trial primary completion date: Oct 2015 --> Oct 2016
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Clinical: RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia (clinicaltrials.gov) - May 5, 2014
P1/2, N=42, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Oct 2015 --> Oct 2016 Recruiting --> Active, not recruiting
- Simulect (basiliximab) / Novartis
Trial primary completion date, Combination therapy: Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients (clinicaltrials.gov) - May 4, 2014
P4, N=40, Completed, Sponsor: Novartis
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2012 --> Jun 2013
- || Trial primary completion date, Combination therapy, Metastases: Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Apr 30, 2014
P4, N=73, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jun 2012 --> Jun 2013 Trial primary completion date: Nov 2014 --> Dec 2016
- everolimus / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Trial primary completion date, Metastases: Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca (clinicaltrials.gov) - Apr 29, 2014
P1/2, N=72, Active, not recruiting, Sponsor: Rutgers, The State University of New Jersey
Trial primary completion date: Nov 2014 --> Dec 2016 Trial primary completion date: Jun 2014 --> Dec 2014
- temozolomide / Generic mfg., everolimus / Generic mfg.
Trial primary completion date, Combination therapy, Metastases: RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors (clinicaltrials.gov) - Apr 29, 2014
P1/2, N=12, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Jun 2014 --> Dec 2014 Trial primary completion date: Jun 2013 --> Sep 2014
- everolimus / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Trial completion date, Metastases: Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca (clinicaltrials.gov) - Apr 29, 2014
P1/2, N=72, Active, not recruiting, Sponsor: Rutgers, The State University of New Jersey
Trial primary completion date: Jun 2013 --> Sep 2014 Trial completion date: Jun 2014 --> Dec 2014
- temozolomide / Generic mfg., everolimus / Generic mfg.
Trial completion date, Combination therapy, Metastases: RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors (clinicaltrials.gov) - Apr 29, 2014
P1/2, N=12, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Trial completion date: Jun 2014 --> Dec 2014 Trial completion date: Sep 2013 --> Sep 2015
- everolimus / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Enrollment closed, Metastases: Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca (clinicaltrials.gov) - Apr 29, 2014
P1/2, N=72, Active, not recruiting, Sponsor: Rutgers, The State University of New Jersey
Trial completion date: Sep 2013 --> Sep 2015 Recruiting --> Active, not recruiting
- everolimus / Generic mfg.
Biomarker, Trial withdrawal: Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer (clinicaltrials.gov) - Apr 29, 2014
P1, N=0, Withdrawn, Sponsor: University of Michigan Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Withdrawn
- everolimus / Generic mfg.
Biomarker, Enrollment change: Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer (clinicaltrials.gov) - Apr 29, 2014
P1, N=0, Withdrawn, Sponsor: University of Michigan Cancer Center
Recruiting --> Withdrawn N=40 --> 0
- everolimus / Generic mfg.
Enrollment closed: NFC-RAD001: Everolimus for Children With NF1 Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas (clinicaltrials.gov) - Apr 28, 2014
P2, N=23, Active, not recruiting, Sponsor: University of Alabama at Birmingham
N=40 --> 0 Recruiting --> Active, not recruiting
- Rituxan (rituximab) / Roche
Enrollment closed: Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia (clinicaltrials.gov) - Apr 28, 2014
P1/2, N=70, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
New P1 trial, Metastases: Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer (clinicaltrials.gov) - Apr 27, 2014
P1, N=43, Not yet recruiting, Sponsor: SCRI Development Innovations, LLC
- metformin / Generic mfg., everolimus / Generic mfg., exemestane / Generic mfg.
Enrollment closed, Metastases: Exemestane-RAD001-Metformin (clinicaltrials.gov) - Apr 27, 2014
P2, N=40, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- everolimus / Generic mfg., sorafenib / Generic mfg.
Enrollment change, Combination therapy, Metastases: Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors (clinicaltrials.gov) - Apr 26, 2014
P1, N=21, Completed, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting N=30 --> 21
- everolimus / Generic mfg., sorafenib / Generic mfg.
Trial completion, Combination therapy, Metastases: Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors (clinicaltrials.gov) - Apr 26, 2014
P1, N=21, Completed, Sponsor: Dana-Farber Cancer Institute
N=30 --> 21 Active, not recruiting --> Completed
- everolimus / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
Clinical: Effect of Everolimus on the Pharmacokinetics of Tacrolimus in Renal Transplant Patients (clinicaltrials.gov) - Apr 23, 2014
P4, N=70, Recruiting, Sponsor: National Taiwan University Hospital
Active, not recruiting --> Completed Initiation date: Mar 2014 --> Apr 2014
- everolimus / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
Clinical: Effect of Everolimus on the Pharmacokinetics of Tacrolimus in Renal Transplant Patients (clinicaltrials.gov) - Apr 23, 2014
P4, N=70, Recruiting, Sponsor: National Taiwan University Hospital
Initiation date: Mar 2014 --> Apr 2014 Not yet recruiting --> Recruiting
- | everolimus / Generic mfg.
Trial initiation date: Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS) (clinicaltrials.gov) - Apr 22, 2014
P2, N=25, Recruiting, Sponsor: Baylor College of Medicine
Not yet recruiting --> Recruiting Initiation date: Dec 2013 --> Apr 2014
- | everolimus / Generic mfg.
Enrollment open: Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS) (clinicaltrials.gov) - Apr 22, 2014
P2, N=25, Recruiting, Sponsor: Baylor College of Medicine
Initiation date: Dec 2013 --> Apr 2014 Not yet recruiting --> Recruiting
- ||||| xentuzumab (BI-836845) / Boehringer Ingelheim
New P2 trial, Combination therapy, Metastases: BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer (clinicaltrials.gov) - Apr 21, 2014
P2, N=198, Not yet recruiting, Sponsor: Boehringer Ingelheim